// App-Quantinova.ai

71 : Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer.

Researchers

Presenter

  • Azim Jalali

Principal Investigators

  • Hui-Li Wong

  • Rachel Wong

  • Margaret Lee

  • Lucy Gately

  • Matthew Loft

  • Jeremy David Shapiro

  • Suzanne Kosmider

  • Jeanne Tie

  • Sumitra Ananda

  • Justin Yeung

  • Ross Jennens

  • Belinda Lee

  • Joseph James McKendrick

  • Lionel Lim

  • Muhammad Adnan Khattak

  • Peter Gibbs

Medical Centers

  • Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia

  • The Walter and Eliza Hall Institute of Medical Research & Peter MacCallum Cancer Centre, Melbourne, Australia

  • Austin Health, Melbourne, Australia

  • Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

  • The Walter and Eliza Hall Institute, Melbourne, Australia

  • Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

  • Cabrini Health, Malvern, Australia

  • Department of Medical Oncology, Western Health, Melbourne, Australia

  • Department of Medical Oncology, Western Health, Melbourne, Australia

  • Peter Macallum Cancer Institute, Melbourne, Australia

  • Wetsern Health, Foostcray, Australia

  • Epworth Hospital, Richmond Vic, Australia

  • Imperial College, London, United Kingdom

  • Ringwood Private Hospital, Doncaster East, Australia

  • Royal Perth Hospital, Perth, Western Australia, Australia

  • Royal Melbourne Hospital, Melbourne, Australia

Locations

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • TAS102

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved